drugset
drugset / Trial / NCT06331650

A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer

NCT06331650 ↗

Phase 2 Unknown 30 enrolled Guangzhou Institute of Respiratory Disease
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and tolerability of carbognilumab combined with chemotherapy as the first-line treatment for patients with STK11 mutated advanced or postoperative recurrent non-small cell lung cancer (NSCLC).

Timeline

Start
2023-08-09
Primary completion
2025-08
Completion
2025-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Cadonilimab Monoclonal antibody 10 mg/kg —

Indications

non-small cell lung carcinoma